- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dendreon Sees Light at the End of the Provenge Tunnel
The Canadian company Valeant Pharmaceuticals International Inc has reached an agreement to buy the prostate cancer immunotherapy from Dendreon Corp.
Valeant Pharmaceuticals International Inc. said late Thursday it has reached a tentative deal to buy the prostate- cancer drug Provenge and other assets from Dendreon Corp. for $296 million in cash.
Quebec-based Valeant said it has entered into a so-called stalking-horse agreement, which means it is the preferred bidder and the company would receive an unspecified breakup fee and reimbursed expenses if its bid doesn't win the auction for Dendreon's assets. A bankruptcy court also must approve Valeant's stalking-horse bid and the sale, Valeant said.
Read complete news on Nasdaq: http://bit.ly/18CptIA
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
